Tim-3 expression on tumor-infiltrating PD-1+CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma

Cancer Research

Volumn 77, Issue 5, 2017, Pages 1075-1082

  Granier, Clémence ^a   Dariane, Charles ^a,b   Combe, Pierre ^a,b   Verkarre, Virginie ^b   Urien, Saïk ^c,d   Badoual, Cécile ^a,b   Roussel, Hélène ^a,b   Mandavit, Marion ^a   Ravel, Patrice ^d   Sibony, Mathilde ^e   Biard, Lucie ^f   Radulescu, Camélia ^g   Vinatier, Emeline ^a,b   Benhamouda, Nadine ^a,b   Peyromaure, Michael ^e   Oudard, Stéphane ^a,b   Méjean, Arnaud ^b   Timsit, Marc Olivier ^b   Gey, Alain ^a,b   Tartour, Eric ^a,b  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Centre de Recherches Cliniques Psychanalytique   (France)

^d INSERM   (France)

^e Université de Montpellier 1 et 2 ^*  (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g FOCH HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VIRUS CELLULAR RECEPTOR 2; PROGRAMMED DEATH 1 RECEPTOR; HAVCR2 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PD1+ CD8+ T CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; BIOSYNTHESIS; COHORT ANALYSIS; IMMUNOLOGY; KIDNEY TUMOR; PATHOLOGY; RENAL CELL CARCINOMA; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION;

CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOPHENOTYPING; KIDNEY NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS;

EID: 85015817432     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0274     Document Type: Article

References (36)

1. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 2015;42: 587-600.
2. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348: 56-61.
3. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515: 568-71.
4. Fourcade J, Sun Z, BenallaouaM, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207: 2175-86.
5. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207: 2187-94.
6. Baitsch L, Fuertes-Marraco SA, Legat A,Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol 2012;33: 364-72.
7. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015;15: 486-99.
8. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007;13: 709s-715s.
9. Giraldo NA, Becht E, Pages F, Skliris G, Verkarre V, Vano Y, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res 2015;21: 3031-40.
10. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype inmice with disseminated acute myelogenous leukemia. Blood 2011;117: 4501-10.
11. Thommen DS, Schreiner J, Muller P, Herzig P, Roller A, Belousov A, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res 2015;3: 1344-55.
12. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015;212: 139-48.
13. Zheng H, Guo X, Tian Q, Li H, Zhu Y. Distinct role of Tim-3 in systemic lupus erythematosus and clear cell renal cell carcinoma. Int J Clin ExpMed 2015;8: 7029-38.
14. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73: 128-38.
15. R Core Team. R : A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
16. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A 2008;105: 15016-21.
17. Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009; 27: 1470-6.
18. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013;139: 667-76.
19. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010;138: 1429-40.
20. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 2015;212: 1125-37.
21. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012;122: 1271-82.
22. Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RCJr, Sams SB, et al. PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer. Cancer Immunol Res 2015;3: 620-30.
23. Takamura S, Tsuji-Kawahara S, Yagita H, Akiba H, Sakamoto M, Chikaishi T, et al. Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol 2010;184: 4696-707.
24. Jin HT, Anderson AC, Tan WG, West EE,Ha SJ, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010;107: 14733-8.
25. Cai C, Xu YF, Wu ZJ, Dong Q, Li MY, Olson JC, et al. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma. World J Urol 2016;34: 561-7.
26. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. IFN-A directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 2011;186: 2772-9.
27. Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun 2015;6: 6072.
28. Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V, et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013;2: E23562.
29. Tang D, Lotze MT. Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol 2012;13: 808-10.
30. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012;13: 832-42.
31. Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S, et al. The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res 2015;3: 999-1007.
32. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, et al. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013;2: E23849.
33. van Esch EM, van Poelgeest MI, Kouwenberg S, Osse EM, Trimbos JB, Fleuren GJ, et al. Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival. Int J Cancer 2015;136: E95-106.
34. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107: 7875-80.
35. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61: 5132-6.
36. Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 2015;107; pii: Dju435.